Bao Y, Yang S, Zhao H, Wang Y, Li K, Liu X
BMC Pulm Med. 2024; 24(1):176.
PMID: 38609879
PMC: 11015635.
DOI: 10.1186/s12890-024-02976-0.
Tian Y, Tsujisaka Y, Li V, Tani K, Lucena-Cacace A, Yoshida Y
Front Cell Dev Biol. 2022; 10:1001453.
PMID: 36438566
PMC: 9692097.
DOI: 10.3389/fcell.2022.1001453.
Hobby G, Clark R, Woywodt A
Clin Kidney J. 2022; 15(10):1971-1972.
PMID: 36158154
PMC: 9494524.
DOI: 10.1093/ckj/sfac116.
Jefferies R, Puttagunta H, Krishnan A, Irish A, Swaminathan R, Olynyk J
Front Med (Lausanne). 2022; 9:722058.
PMID: 35273970
PMC: 8901721.
DOI: 10.3389/fmed.2022.722058.
Dutta S, Basak B, Bhunia B, Chakraborty S, Dey A
3 Biotech. 2017; 4(5):523-531.
PMID: 28324387
PMC: 4162898.
DOI: 10.1007/s13205-013-0189-2.
Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.
Gupta A, Sharma D, Meena J, Pandya S, Sachan M, Kumar S
Pharm Res. 2016; 33(8):1899-912.
PMID: 27095353
DOI: 10.1007/s11095-016-1926-0.
Spatial and cellular characterization of mTORC1 activation after spinal cord injury reveals biphasic increase mainly attributed to microglia/macrophages.
Kjell J, Codeluppi S, Josephson A, Abrams M
Brain Pathol. 2014; 24(6):557-67.
PMID: 24576152
PMC: 4347463.
DOI: 10.1111/bpa.12135.
Correction of glycogen storage disease type III with rapamycin in a canine model.
Yi H, Brooks E, Thurberg B, Fyfe J, Kishnani P, Sun B
J Mol Med (Berl). 2014; 92(6):641-50.
PMID: 24509886
DOI: 10.1007/s00109-014-1127-4.
Immunostimulatory activity of lifespan-extending agents.
Bravo-San Pedro J, Senovilla L
Aging (Albany NY). 2014; 5(11):793-801.
PMID: 24389041
PMC: 3868722.
DOI: 10.18632/aging.100619.
Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.
Sofroniadou S, Goldsmith D
Drug Saf. 2011; 34(2):97-115.
PMID: 21247219
DOI: 10.2165/11585040-000000000-00000.
Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: implications for treatment of port-wine stain birthmarks.
Loewe R, Oble D, Valero T, Zukerberg L, Mihm Jr M, Nelson J
J Cutan Pathol. 2010; 37 Suppl 1:76-82.
PMID: 20482679
PMC: 3160814.
DOI: 10.1111/j.1600-0560.2010.01520.x.
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Ladoire S, Beynat C, Diaz P, Coudert B, Favier L, Ghiringhelli F
Med Oncol. 2009; 27(3):938-41.
PMID: 19768583
DOI: 10.1007/s12032-009-9311-z.
Comprehensive lung injury pathology induced by mTOR inhibitors.
Aparicio G, Calvo M, Medina V, Fernandez O, Jimenez P, Lema M
Clin Transl Oncol. 2009; 11(8):499-510.
PMID: 19661024
DOI: 10.1007/s12094-009-0394-y.
Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.
McEwan P, Dixon S, Baboolal K, Conway P, Currie C
Pharmacoeconomics. 2006; 24(1):67-79.
PMID: 16445304
DOI: 10.2165/00019053-200624010-00006.
